NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson declared a quarterly dividend on Thursday, October 18th. Shareholders of record on Tuesday, November 27th will be paid a dividend of $0.90 per share on Tuesday, December 11th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.44%. The ex-dividend date of this dividend is Monday, November 26th. View Johnson & Johnson's Dividend History.

Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday, October, 16th. The company reported $2.05 earnings per share for the quarter, beating analysts' consensus estimates of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson will be holding an earnings conference call on Tuesday, January 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Johnson & Johnson updated its FY18 earnings guidance on Monday, October, 29th. The company provided earnings per share guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.16.

15 analysts have issued 12 month price targets for Johnson & Johnson's shares. Their predictions range from $110.00 to $160.00. On average, they expect Johnson & Johnson's share price to reach $142.2727 in the next twelve months. This suggests that the stock has a possible downside of 3.7%. View Analyst Price Targets for Johnson & Johnson.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.

Headlines about JNJ stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).

Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.96%), Bank of New York Mellon Corp (1.26%), Massachusetts Financial Services Co. MA (1.11%), Morgan Stanley (0.85%), Legal & General Group Plc (0.48%) and Fisher Asset Management LLC (0.42%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

JNJ stock was sold by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Trust & Banking Corp, Fisher Asset Management LLC, American Century Companies Inc., Skandinaviska Enskilda Banken AB publ , Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Assenagon Asset Management S.A. and Janus Henderson Group PLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

JNJ stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Morgan Stanley, Los Angeles Capital Management & Equity Research Inc., Mondrian Investment Partners LTD, Cornerstone Wealth Management LLC, Flossbach Von Storch AG, Bank of New York Mellon Corp and Teachers Advisors LLC. View Insider Buying and Selling for Johnson & Johnson.

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNJ stock can currently be purchased for approximately $147.7350.

Johnson & Johnson has a market capitalization of $393.05 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

The official website for Johnson & Johnson is http://www.jnj.com.

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.